Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Novavax Licenses Matrix-M Adjuvant to Pfizer in $530M Deal

Fineline Cube Jan 22, 2026
Company Deals

BioRay Pharmaceutical Files HKEX IPO, Backed by First‑in‑Class Autoimmune and Oncology Pipeline

Fineline Cube Jan 22, 2026
Company Deals

BMS Partners with Microsoft on AI‑Powered NSCLC Detection Platform

Fineline Cube Jan 22, 2026
Company Deals

Bayer Partners with Vanderbilt in 5‑Year Deal to Accelerate Cardio‑Renal Drug Discovery

Fineline Cube Jan 22, 2026
Company Deals

Hangzhou Diagens Biotechnology Files HKEX IPO for Medical Imaging AI Platform

Fineline Cube Jan 22, 2026
Company Drug Policy / Regulatory

Merson’s Bemejing Wins First CNMR “Overseas Version” Drug Price Certificate

Fineline Cube Jan 21, 2026
Company Drug

Enhertu Wins China NMPA Approval for Second‑Line HER2‑Positive Gastric Cancer

Fineline Cube Jan 22, 2026
Company Drug

AstraZeneca’s Imfinzi Wins China Approval for Endometrial Cancer, Securing Seventh Indication

Fineline Cube Jan 22, 2026
Policy / Regulatory

CDE Releases 89th Batch of Reference Preparations for Generic Quality Consistency

Fineline Cube Dec 10, 2024

The Center for Drug Evaluation (CDE) in China has announced the selection of the 89th...

Company Deals

Jiangsu Hengrui Pharmaceuticals Plans Secondary Listing on Hong Kong Stock Exchange

Fineline Cube Dec 10, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has confirmed reports regarding its intention to make...

Company Drug

Keymed Biosciences Presents CM336 Data for Relapsed Multiple Myeloma at ASH Annual Meeting

Fineline Cube Dec 10, 2024

China-based Keymed Biosciences Inc., (HKG: 2162) has announced the presentation of the latest data from...

Company Drug

Antengene’s Xpovio Showcases Positive Results in Phase III BENCH and Phase I/II TOUCH Studies at ASH 2024

Fineline Cube Dec 10, 2024

China-based Antengene Corporation Limited (Antengene, HKG: 6996) announced the presentation of the latest results from...

Company Drug

Lee’s Pharmaceutical Receives NMPA Approval for Generic Glaucoma Treatments

Fineline Cube Dec 10, 2024

China-based Lee’s Pharmaceutical Holdings Ltd (HKG: 0950) subsidiary, Zhaoke Ophthalmology Ltd (HKG: 6622), has announced...

Policy / Regulatory

NMPA Proposes Draft for Simplified Registration of Traditional Chinese Medicines from Hong Kong and Macao

Fineline Cube Dec 10, 2024

The National Medical Products Administration (NMPA) has issued the “Notification on Simplifying the Registration and...

Policy / Regulatory

China’s NHSA and NHC Issue Guidelines to Enhance Volume-based Procurement Mechanism

Fineline Cube Dec 10, 2024

The National Healthcare Security Administration (NHSA) and National Health Commission (NHC) of China have released...

Company Drug

CSPC Pharmaceutical Group’s SYHX2011 for Metastatic Breast Cancer Accepted for NMPA Review

Fineline Cube Dec 10, 2024

China-based CSPC Pharmaceutical Group Co., Ltd. (HKG: 1093) has announced that the National Medical Products...

Company Drug

GSK’s Nucala Receives FDA Review for COPD Indication Based on MATINEE Study Data

Fineline Cube Dec 10, 2024

UK-based pharmaceutical giant GSK (NYSE: GSK) has announced that the US Food and Drug Administration...

Company Deals

Hantech Medical Device Co., Ltd Acquires BD’s Villamarzana Factory to Expand Manufacturing

Fineline Cube Dec 10, 2024

China-based Hantech Medical Device Co., Ltd, a Contract Development Manufacturing Organization (CDMO) specializing in medical...

Company Deals

Precision Biotech and T&L Biotechnology Form Partnership to Advance Cell and Gene Therapies

Fineline Cube Dec 10, 2024

China-based Precision Biotech has announced a strategic partnership with compatriot firm T&L Biotechnology Co., Ltd....

Company Medical Device

MicroPort Scientific Corp. Launches FireFalcon Balloon for Coronary Interventions with NMPA Approval

Fineline Cube Dec 10, 2024

Shanghai-based medical device giant MicroPort Scientific Corp., (HKG: 0853) has announced that it has received...

Company Drug

HuidaGene Therapeutics Initiates HERO Trial for RNA-Editing Therapy HG204 in MECP2 Duplication Syndrome

Fineline Cube Dec 10, 2024

Shanghai-based HuidaGene Therapeutics has announced the first subject dosing of the HERO clinical trial, which...

Company Drug

Simcere Pharmaceutical’s SIM0508 Reaches First Patient Dosing in Global Clinical Study

Fineline Cube Dec 10, 2024

China-based Simcere Pharmaceutical Group Limited’s (HKG: 2096) subsidiary, Simcere Zaiming, has announced the first patient...

Company Deals

Livzon Pharmaceutical Group Inks Influenza Vaccine Patent Deal with South China Vaccine Corporation

Fineline Cube Dec 10, 2024

China-based Livzon Pharmaceutical Group Inc. (HKG: 1513) has entered into a significant patent and technology...

Company Deals

WuXi AppTec’s Subsidiary Invests EUR 20 Million in Jeito II S.L.P. for Growth Expansion

Fineline Cube Dec 9, 2024

China-based Contract Development and Manufacturing Organization (CDMO) WuXi AppTec Co., Ltd (SHA: 603259) has announced...

Company Drug

TJ Biopharma and Jumpcan Pharmaceutical Announce NMPA Review of Eftansomatropin Alfa BLA

Fineline Cube Dec 9, 2024

Chinese partners TJ Biopharma and Jumpcan Pharmaceutical (SHA: 600566) have jointly announced that the National...

Company Drug

AstraZeneca’s Imfinzi Receives FDA Priority Review for Muscle-Invasive Bladder Cancer

Fineline Cube Dec 9, 2024

UK pharmaceutical giant AstraZeneca (AZ, NASDAQ: AZN) has announced that the US Food and Drug...

Company Drug

Amgen’s Blincyto Meets Primary Endpoint in Phase III AALL1731 Study for Pediatric B-ALL

Fineline Cube Dec 9, 2024

US-based biotechnology company Amgen (NASDAQ: AMGN) has published the results from the Phase III study...

Company Drug

Novartis’ Fabhalta Demonstrates Positive Results in APPULSE-PNH Phase IIIb Study

Fineline Cube Dec 9, 2024

Swiss pharmaceutical major Novartis (NYSE: NVS) has released positive topline results from the APPULSE-PNH Phase...

Posts pagination

1 … 196 197 198 … 612

Recent updates

  • Enhertu Wins China NMPA Approval for Second‑Line HER2‑Positive Gastric Cancer
  • AstraZeneca’s Imfinzi Wins China Approval for Endometrial Cancer, Securing Seventh Indication
  • HeartCare Medical’s Intracranial Drug‑Eluting Stent Gets NMPA Filing Nod
  • Abbott’s TactiFlex Duo Wins CE Mark for Atrial Fibrillation Treatment in Europe
  • Lilly’s Sofetabart Wins FDA Breakthrough Status for Platinum‑Resistant Ovarian Cancer
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Enhertu Wins China NMPA Approval for Second‑Line HER2‑Positive Gastric Cancer

Company Drug

AstraZeneca’s Imfinzi Wins China Approval for Endometrial Cancer, Securing Seventh Indication

Company Medical Device

HeartCare Medical’s Intracranial Drug‑Eluting Stent Gets NMPA Filing Nod

Company Medical Device

Abbott’s TactiFlex Duo Wins CE Mark for Atrial Fibrillation Treatment in Europe

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.